09:00pm Monday 20 November 2017

Spaces are still being sought for a first of a kind international study to help women with Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is the most common hormone disorder in women pre-menopause, affecting millions in the UK. Despite this there are very limited options for treatment.

This study, the first of its kind in the world, is being launched by University Hospital in Coventry and will look at whether adding a drug called Liraglutide will improve symptoms.

Liraglutide is already used for patients with Type 2 Diabetes and has been shown to aid weight loss in some.

Spaces are still available for the innovative LIPOS study (Liraglutide in PCOS study) which takes place over 12 months at University Hospital and is being hosted by the Trust in partnership with Warwick Medical School.

It is looking for women who fit the following criteria:

• Aged 18-50.
• Have already been diagnosed with PCOS, or think they have it and the team will run the tests to see*.

Those taking part in the study will have their travel and parking costs reimbursed and will get support from a dedicated nurse and have easy access to a team including consultants.

Those interested in taking part, or learning more about the study, should contact study nurses Catherine Casas (Catherine.casas@uhcw.nhs.uk) or Sundeep Deo (Sundeep.deo@uhcw.nhs.uk) or call 02476 965249.

 

FOR MORE INFORMATION ON THIS PRESS RELEASE PLEASE CONTACT KERRY BEADLING-BARRON, ON 02476 967597

NOTES TO EDITORS
*Symptoms of PCOS include:
• irregular, or no, periods;
• excess facial and body hair;
• acne;
• being more prone to putting on weight, especially around the stomach area.


Share on:
or:

MORE FROM Drugs Approvals and Trials

Health news